Monitoring cognitive impairment through speech

Winterlight has developed a tablet-based assessment that is fast, objective, and stress-free. By analyzing speech alone, we can detect cognitive impairment associated with dementia and mental illness. Our assessment can be used in life science research, senior care and clinical settings.


A biomarker for clinical research

Paper-based cognitive assessments are slow, subjective and often coarse. Winterlight has developed a speech-based cognitive assessment that analyzes short snippets of speech and uses AI to objectively measure cognition via hundreds of markers in speech and language. Winterlight can support clinical trials and studies for a wide range of central nervous system disorders.

Work with us

Tracking cognitive wellness in senior care

It is challenging to care for seniors with complex medical needs and frequently with cognitive impairments. Combined with your existing health data, we identify seniors at-risk of cognitive or functional decline. Our assessment can help you provide better proactive care at a time when it is most needed to have the greatest impact on the health and happiness of your residents.

Reach us here

Winterlight’s Healthy Aging Study

We are building better tools so that we can identify risk for dementia more quickly and at an earlier age. This will allow researchers to better understand the disease and work towards a cure. If you are healthy and 50 years or older in the Greater Toronto Area, we would like your help on learning the effect of the aging process on the brain.

Tell me more

Developed in partnership with:

What's new

February 2019

Battling Dementia with the Power of AI

Winterlight Labs was featured on TVO's The Agenda with Steve Paikin. The episode titled "Battling Dementia with the Power of AI" showcases Winterlight Lab's partnership with Revera Living.

Read Read More
January 2019

Winterlight Labs, Inc. Enters Collaboration with Johnson & Johnson Innovation to Develop a Digital Biomarker for Diagnosis of Early Stage Alzheimer's Disease

The agreement was facilitated by Johnson & Johnson Innovation LLC. The collaboration will initially focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's Disease (AD), from healthy elderly subjects.

Read Read More
November 2018

Winterlight research accepted to NeurIPS 2018 workshops

Two of our research papers were accepted and will be presented at NeurIPS (the conference previously known as NIPS) workshops next week in Montreal. NeurIPS is the leading machine learning conference - tickets sold out in 20 minutes.

Read Read More
October 2018

Winterlight technology shows positive results of treatment in Phase 1 study of COR388 in Alzheimer’s disease

No significant improvements were observed in Mini Mental State Examination (MMSE) scores or CANTAB measures of cognition between treatment (COR388) and placebo groups. In contrast, Winterlight’s cognitive assessment showed statistically significant improvements from baseline to endpoint in the treatment group, with no such differences seen in the placebo group.

Read Read More

Get in touch

Mailing Address

Winterlight Labs Inc.
Attn: Liam Kaufman
JLABS @ Toronto,
MaRS DD, West Tower
661 University Avenue
Suite 1300
Toronto, ON, M5G 0B7

Send us a message